Akebia Therapeutics Inc (NASDAQ:AKBA) Expected to Post Earnings of -$0.35 Per Share

Brokerages expect Akebia Therapeutics Inc (NASDAQ:AKBA) to report ($0.35) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Akebia Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.41). Akebia Therapeutics posted earnings per share of ($0.60) in the same quarter last year, which indicates a positive year-over-year growth rate of 41.7%. The company is expected to issue its next earnings report on Wednesday, August 14th.

On average, analysts expect that Akebia Therapeutics will report full year earnings of ($1.75) per share for the current fiscal year, with EPS estimates ranging from ($2.28) to ($1.41). For the next fiscal year, analysts forecast that the business will post earnings of ($0.63) per share, with EPS estimates ranging from ($1.66) to $0.38. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Akebia Therapeutics.

Akebia Therapeutics (NASDAQ:AKBA) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.02). The firm had revenue of $72.67 million for the quarter, compared to analysts’ expectations of $83.69 million. Akebia Therapeutics had a negative net margin of 82.14% and a negative return on equity of 45.06%.

A number of brokerages have recently weighed in on AKBA. BidaskClub downgraded Akebia Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 18th. Zacks Investment Research downgraded Akebia Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, March 1st. ValuEngine downgraded Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, June 11th. JPMorgan Chase & Co. assumed coverage on Akebia Therapeutics in a report on Thursday, May 2nd. They issued an “overweight” rating and a $12.00 price objective on the stock. Finally, Citigroup assumed coverage on Akebia Therapeutics in a report on Wednesday, March 20th. They issued a “neutral” rating and a $9.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $13.03.

Large investors have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC grew its holdings in Akebia Therapeutics by 5.9% during the fourth quarter. MetLife Investment Advisors LLC now owns 40,608 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 2,250 shares during the last quarter. Strs Ohio grew its holdings in Akebia Therapeutics by 5.4% during the first quarter. Strs Ohio now owns 45,100 shares of the biopharmaceutical company’s stock valued at $369,000 after purchasing an additional 2,300 shares during the last quarter. Virginia Retirement Systems ET AL grew its holdings in Akebia Therapeutics by 18.2% during the first quarter. Virginia Retirement Systems ET AL now owns 16,200 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 2,500 shares during the last quarter. DekaBank Deutsche Girozentrale grew its holdings in Akebia Therapeutics by 20.5% during the first quarter. DekaBank Deutsche Girozentrale now owns 20,600 shares of the biopharmaceutical company’s stock valued at $170,000 after purchasing an additional 3,500 shares during the last quarter. Finally, Boston Partners grew its holdings in Akebia Therapeutics by 1.3% during the first quarter. Boston Partners now owns 283,044 shares of the biopharmaceutical company’s stock valued at $2,318,000 after purchasing an additional 3,666 shares during the last quarter. Hedge funds and other institutional investors own 70.50% of the company’s stock.

Shares of AKBA traded up $0.21 during trading hours on Friday, reaching $4.84. The company’s stock had a trading volume of 7,308,094 shares, compared to its average volume of 1,156,008. The company has a market cap of $545.70 million, a price-to-earnings ratio of -1.98 and a beta of 1.51. Akebia Therapeutics has a 1-year low of $4.09 and a 1-year high of $10.73. The company has a current ratio of 1.71, a quick ratio of 1.15 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average of $4.85.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.

See Also: What is the Difference Between Common Shares and Convertible Shares?

Get a free copy of the Zacks research report on Akebia Therapeutics (AKBA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.